MyD88-IN-1

CAS No. 2911609-80-6

MyD88-IN-1( —— )

Catalog No. M36865 CAS No. 2911609-80-6

MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 164 In Stock
5MG 150 In Stock
10MG 225 In Stock
25MG 373 In Stock
50MG 454 In Stock
100MG 646 In Stock
200MG Get Quote In Stock
500MG 1330 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MyD88-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family.
  • Description
    MyD88-IN-1 is a potent MyD88 inhibitor. MyD88-IN-1 inhibits the interaction of TLR4 and MyD88 and suppressed the NF-κB pathway. MyD88-IN-1 can be used in research of cancer and inflammatory.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor | NF-κB | MyD88 | TLR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2911609-80-6
  • Formula Weight
    528.54
  • Molecular Formula
    C23H24N6O7S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (189.20 mM; Ultrasonic )
  • SMILES
    N(=O)(=O)C1=C(C=CC(S(NC=2C=CC(OC)=NC2)(=O)=O)=C1)N3CCN(CC4=CC(N(=O)=O)=CC=C4)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen P, et, al. Design, Synthesis, and Bioevaluation of Novel MyD88 Inhibitor c17 against Acute Lung Injury Derived from the Virtual Screen. J Med Chem. 2023 May 25;66(10):6938-6958.?
molnova catalog
related products
  • CP 424174

    CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.

  • Xeligekimab

    Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.

  • Brodalumab

    Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.